Bavarian Nordic

Price Chart

Risk-Adjusted Performance

Also Listed On

Bavarian Nordic (BAVA) Price Performance

Bavarian Nordic (BAVA) trades on Nasdaq Copenhagen in DKK. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at DKK190.30, up 2.17% from the previous close.

Over the past year, BAVA has traded between a low of DKK140.15 and a high of DKK242.10. The stock has gained 19.4% over this period. It is currently 21.4% below its 52-week high.

Bavarian Nordic has a market capitalization of $18.52B, with a price-to-earnings ratio of 10.39.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.